The presence of germline mutations in DDX41 or CEBPA could inform clinicians about the relative risks of developing hematological tumors, the possible age at onset and the prognosis of the possible disease. This evidence concerns the gene CEBPA and hematopoietic and lymphoid system neoplasm.